Regenerex Pharma (RGPX) Accumulated Expenses (2011 - 2025)

Regenerex Pharma (RGPX) has 13 years of Accumulated Expenses data on file, last reported at $154357.0 in Q3 2025.

• Accumulated Expenses for Q3 2025 came in at $154357.0, down 78.12% year-over-year; the trailing twelve-month figure through Sep 2025 was $154357.0 (down 78.12% YoY), and the FY2025 annual result was $88268.0, down 82.76% from the prior year.
• Accumulated Expenses slipped to $154357.0 in Q3 2025 per RGPX's latest filing, from $862869.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $862869.0 in Q2 2025 and troughed at $14240.0 in Q2 2023.
• A 5-year average of $276453.9 and a median of $221192.0 in 2021 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses tumbled 83.97% in 2023, then surged 4174.8% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $221192.0 in 2021, then changed by 0.0% to $221192.0 in 2022, then slumped by 73.56% to $58492.0 in 2023, then soared by 1271.99% to $802502.0 in 2024, then tumbled by 80.77% to $154357.0 in 2025.
• Business Quant data shows RGPX's Accumulated Expenses at $154357.0 in Q3 2025, $862869.0 in Q2 2025, and $88268.0 in Q1 2025.